Intrazolina (Cefazolin)

Cefazolin exerts its antibacterial effect by binding to penicillin‑binding proteins on the bacterial cell wall, inhibiting the transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability and bacterial lysis, primarily against susceptible Gram‑positive and some Gram‑negative organisms.

The dosage of Intrazolina is determined by the prescribing clinician based on the infection type, severity, patient weight, renal function and route of administration. Dosing regimens are individualized and should follow local prescribing guidelines.

Cefazolin is classified as pregnancy category B, indicating no evidence of risk in animal studies and insufficient human data. It may be used during pregnancy only when the potential benefit justifies the risk. Limited data suggest it is excreted in breast milk in small amounts; breastfeeding decisions should be made with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Compared with later‑generation cephalosporins, cefazolin offers strong activity against Gram‑positive cocci and limited Gram‑negative coverage, making it suitable for many surgical prophylaxis and uncomplicated infections. It generally has a favorable safety profile and lower cost, but may be less effective against resistant organisms that require broader‑spectrum agents.

Intrazolina should be stored below 25 °C in its original packaging, protected from moisture and light. Vials must be kept upright, and any solution should be inspected for particulate matter before administration. Do not freeze the product.

Intrazolina is supplied as an injectable solution for intramuscular or intravenous injection. Administration is performed by a qualified healthcare professional, typically as a single dose or multiple doses depending on the clinical indication and patient factors.

The most serious adverse reactions include anaphylaxis, severe skin reactions such as Stevens‑Johnson syndrome, and Clostridioides difficile‑associated colitis. Patients should be monitored for signs of hypersensitivity, rash, or persistent diarrhea, and treatment should be discontinued if severe reactions occur.

Intrazolina should be avoided in individuals with a documented hypersensitivity to cefazolin, other cephalosporins, or penicillins. Caution is also advised for patients with severe renal impairment, neonates, and those receiving interacting medications listed under major interactions.